Management ChangeJul 7, 2026, 04:26 PM
Eupraxia Pharmaceuticals Appoints 3 New Directors to Board
AI Summary
Eupraxia Pharmaceuticals Inc. announced the appointment of three new industry leaders, Robert Bazemore, Amy Pott, and Dr. Helen Thackray, to its Board of Directors. These appointments are expected to strengthen the company's expertise in late-stage drug development, commercial strategy, and global product launches, particularly as it advances its EP-104GI program and expands its pipeline. The company also acknowledged the departure of long-serving directors Paul Geyer and Michael Wilmink.
Key Highlights
- Eupraxia Pharmaceuticals appointed Robert Bazemore to its Board of Directors.
- Amy Pott was appointed to Eupraxia's Board of Directors.
- Dr. Helen Thackray joined Eupraxia's Board of Directors.
- New directors bring expertise in late-stage drug development, commercial strategy, and global product launches.
- Robert Bazemore previously served as President/CEO of Epizyme Inc. and COO of Synageva BioPharma Corp.
- Amy Pott held roles as Global CCO at enGene and SVP at Astellas Pharma.
- Dr. Thackray was Chief R&D Officer at BioCryst Pharmaceuticals and CMO at GlycoMimetics Inc.
- Paul Geyer and Michael Wilmink departed from the Board of Directors.
Price Impact
More from EPRX